Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are newly starting ibrutinib treatment for chronic lymphocytic leukaemia (CLL) — either for the first time or after the condition has returned — where treatment has just begun or started within the last 8 days at most
- People who have agreed to take part in a personalised physical activity program as part of the study
- People who have access to a compatible electronic device, such as a smartphone, laptop, or tablet
- People who have internet access at home and an active email address
- People who have agreed to wear a connected (smart) watch 24 hours a day for the entire duration of the study
Who may not be able to join:
- People who are pregnant or planning to become pregnant during the study period
- People who are unable to do physical activity, or for whom physical activity has been considered unsafe
- People who have taken part in another experimental drug or device study within the 90 days before joining this trial
- People who are currently enrolled in another interventional clinical study
- People who may have significant difficulty using digital tools independently
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Cilag S.A.S., France Clinical Trial, Janssen Cilag S.A.S.
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in Health-related Quality of Life (HRQoL) by Using Functional Assessment of Cancer Therapy General (FACT-G) Total Score at Month 4.5
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.